VCN-01 is under clinical development by VCN Biosciences and currently in Phase II for Retinoblastoma. According to GlobalData, Phase II drugs for Retinoblastoma have a 60% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how VCN-01’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
VCN-01 is under development for the treatment of advanced solid tumors including metastatic colorectal cancer, metastatic pancreatic adenocarcinoma and serous epithelial ovarian cancer, recurrent metastatic squamous cell carcinoma of the head and neck, high-grade glioma or brain metastases, pancreatic adenocarcinoma, retinoblastoma and glioblastoma multiforme. It is administered by intravenous, intravitreal and intratumoral route. It is a tumor-selective replication-competent adenovirus expressing PH20 hyaluronidase. The drug candidate is a genetically engineered adenovirus that is developed based on hyaluronidase technology. It was also under development for the treatment of osteosarcoma.
VCN Biosciences overview
VCN Biosciences (VCN) is a clinical-stage immuno-oncology company focused on the development of the oncolytic adenoviruses for the treatment of tumors. The company’s lead product candidate VCN-01, a tumor-selective replication-competent adenovirus expressing PH20 hyaluronidase degrades a structural element of tumor extracellular matrix; and used for the treatment of refractory tumors, such as pancreatic adenocarcinomas. VCN utilizes oncolytic adenovirus technology platform to design selective and efficient agents that replicate and self-amplify in tumor cells. The company works in partnership with Undacio Hospital Sant Joan De Deu, Reig Jofre Group, and Institut Catala Doncologia for the development of therapeutic agents against tumors. VCN is headquartered in Sant Cugat del Valles, Barcelona, Spain.
For a complete picture of VCN-01’s drug-specific PTSR and LoA scores, buy the report here.